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Five Years of GWAS Discovery
Peter M. Visscher,1,2,* Matthew A. Brown,1 Mark I. McCarthy,3,4 and Jian Yang5The past five years have seenmany scientific and biological discov-
eries made through the experimental design of genome-wide asso-
ciation studies (GWASs). These studies were aimed at detecting
variants at genomic loci that are associated with complex traits
in the population and, in particular, at detecting associations
between common single-nucleotide polymorphisms (SNPs) and
common diseases such as heart disease, diabetes, auto-immune
diseases, and psychiatric disorders. We start by giving a number
of quotes from scientists and journalists about perceived problems
with GWASs. We will then briefly give the history of GWASs and
focus on the discoveries made through this experimental design,
what those discoveries tell us and do not tell us about the genetics
and biology of complex traits, and what immediate utility has
come out of these studies. Rather than giving an exhaustive review
of all reported findings for all diseases and other complex traits, we
focus on the results for auto-immune diseases and metabolic
diseases. We return to the perceived failure or disappointment
about GWASs in the concluding section.
Introduction: Have GWASs Been a Failure?
In the past five years, genome-wide association studies
(GWASs) have led to many scientific discoveries, and yet
at the same time, many people have pointed to various
problems and perceived failures of this experimental
design. Let us begin by considering a number of criticisms
that have been made against GWASs. We do not list these
quotes to discredit any of the scientists or journalists
involved, nor to deliberately cite them out of context.
Rather, they serve to confirm that the points we discuss
in this review are related to beliefs held by a significant
number of scientific commentators and therefore warrant
consideration.
From an interview with Sir Alec Jeffreys, ESHG Award
Lecturer 2010:
‘‘One of the great hopes for GWAS was that, in the
same way that huge numbers of Mendelian disorders
were pinned down at the DNA level and the gene
and mutations involved identified, it would be
possible to simply extrapolate from single gene disor-
ders to complex multigenic disorders. That really
hasn’t happened. Proponents will argue that it has
worked and that all sorts of fascinating genes that
predispose to or protect against diabetes or breast
cancer, for example, have been identified, but the
fact remains that the bulk of the heritability in these
conditions cannot be ascribed to loci that have1University of Queensland Diamantina Institute, Princess Alexandra Hospital,
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Theemerged from GWAS, which clearly isn’t going to
be the answer to everything.’’
From McCLellan and King, Cell 20101:
‘‘To date, genome-wide association studies (GWAS)
have published hundreds of common variants
whose allele frequencies are statistically correlated
with various illnesses and traits. However, the vast
majority of such variants have no established biolog-
ical relevance to disease or clinical utility for prog-
nosis or treatment.’’
‘‘An odds ratio of 3.0, or even of 2.0 depending on
population allele frequencies, would be robust to
such population stratification. However, odds ratios
of the magnitude generally detected by GWAS
(<1.5) can frequently be explained by cryptic popu-
lation stratification, regardless of the p value associ-
ated with them.’’
‘‘More generally, it is now clear that common risk
variants fail to explain the vast majority of genetic
heritability for any human disease, either individu-
ally or collectively (Manolio et al., 2009).’’
‘‘The general failure to confirm common risk vari-
ants is not due to a failure to carry out GWAS
properly. The problem is underlying biology, not
the operationalization of study design. The common
disease–common variant model has been the
primary focus of human genomics over the last
decade. Numerous international collaborative efforts
representing hundreds of important human diseases
and traits have been carried out with large well-char-
acterized cohorts of cases and controls. If common
alleles influenced common diseases, many would
have been found by now. The issue is not how to
develop still larger studies, or how to parse the data
still further, but rather whether the common
disease–common variant hypothesis has now been
tested and found not to apply to most complex
human diseases.’’
From Nicholas Wade in the New York Times, March 20
2011:
‘‘More common diseases, like cancer, are thought to
be caused by mutations in several genes, and finding
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human genome project. To that end, medical genet-
icists have invested heavily over the last eight years
in an alluring shortcut. But the shortcut was based
on a premise that is turning out to be incorrect. Scien-
tists thought the mutations that caused common
diseases would themselves be common. So they first
identified the common mutations in the human
population in a $100 million project called the
HapMap. Then they compared patients’ genomes
with those of healthy genomes. The comparisons
relied on ingenious devices called SNP chips, which
scan just a tiny portion of the genome. (SNP,
pronounced ‘‘snip,’’ stands for single nucleotide
polymorphism.) These projects, called genome-wide
association studies, each cost around $10 million or
more. The results of this costly international exercise
have been disappointing. About 2,000 sites on the
human genome have been statistically linked with
various diseases, but in many cases the sites are
not inside working genes, suggesting there may be
some conceptual flaw in the statistics. And in most
diseases the culprit DNA was linked to only a small
portion of all the cases of the disease. It seemed that
natural selection has weeded out any disease-causing
mutation before it becomes common.’’
From Tim Crow, Molecular Psychiatry 20112:
‘‘There comes a point at which the genetic skeptic
can be pardoned the suggestion that if the genes
are so small and so multiple, what they are hardly
matters, the dividing line between polygenes and
no genes is of little practical consequence. Have we
reached this point’’?
From a commentary article by Jonathan Latham, on
guardian.co.uk, 17 April 2011:
‘‘Among all the genetic findings for common
illnesses, such as heart disease, cancer and mental
illnesses, only a handful are of genuine significance
for human health. Faulty genes rarely cause, or even
mildly predispose us, to disease, and as a consequence
the science of human genetics is in deep crisis.
Since the Collins paper [Manolio et al. 20093] was
published nothing has happened to change that
conclusion. It now seems that the original twin-
study critics were more right than they imagined.
The most likely explanation for why genes for
common diseases have not been found is that, with
few exceptions, they do not exist.’’
These quotes raise a number of different issues about
the methodology, research outcomes, and utility of the
research findings. The pertinent points made in these
quotes are:
(1) GWASs are founded on a flawed assumption that
genetics plays an important role in the risk to
common diseases;8 The American Journal of Human Genetics 90, 7–24, January 13, 201(2) GWASs have been disappointing in not explaining
more genetic variation in the population;
(3) GWASs have not delivered meaningful, biologically
relevant knowledge or results of clinical or any
other utility; and
(4) GWAS results are spurious.
In this review we will briefly give the history of GWASs
and then focus on the discoveries made through this
experimental design, what those discoveries tell us and
do not tell us about the genetics and biology of complex
traits, and what immediate utility has come out of these
studies. We will focus on the results for auto-immune
diseases and metabolic diseases, although there have
been important findings for other diseases and complex
traits. In the concluding section, we will again consider
the perceived failure or disappointment of GWASs.
What Are GWASs, and How Did We Get There?
Attempts to use linkage analysis to map genomic loci that
have an effect on disease or other complex traits have
been ubiquitous in the last two decades. Gene mapping
by linkage relies on the cosegregation of causal variants
with marker alleles within pedigrees. We define and
discuss what we mean by ‘‘causal’’ in Box 1. Because the
number of recombination events per meiosis is relatively
small, tagging a causal variant requires only a few genetic
markers per chromosome. The downside of the small
number of recombination events is that the mapping
resolution, i.e., how close to the causal variant one can
get through linked markers, is typically low. Linkage
mapping has been extremely successful in mapping genes
and gene variants affecting Mendelian traits (e.g., single-
gene disorders).4 Mapping loci underlying common
diseases and, in particular, identifying causative muta-
tions have had much less success. There are many reasons
for the failure of linkage analyses to reliably identify
complex-trait loci in human pedigrees. One reason is
that the effect sizes (‘‘penetrance’’) of individual causal
variants are too small to allow detection via cosegregation
within pedigrees.
GWASs are based upon the principle of linkage disequi-
librium (LD) at the population level. LD is the nonrandom
association between alleles at different loci. It is created by
evolutionary forces such as mutation, drift, and selection
and is broken down by recombination.5 Generally, loci
that are physically close together exhibit stronger LD
than loci that are farther apart on a chromosome. The
larger the (effective) population size, the weaker the LD
for a given distance.6 (Linkage analysis exploits the large
LD within pedigrees.) The genomic distance at which LD
decays determines how many genetic markers are needed
to ‘‘tag’’ a haplotype, and the number of such tagging
markers is much smaller than the total number of
segregating variants in the population. For example,
a selection of approximately 500,000 common SNPs in
the human genome is sufficient to tag common variation2
Box 1. What Is a Causal Variant?
New mutations that contribute to an increase or
decrease in risk to disease arise in populations all
the time. Some of these mutations can reach an
appreciable frequency in the population, for
example by random drift or by natural selection.
As discussed in the main text, these mutations will
be associated with other variants in the genome
through LD. Such associations will include those
with SNPs that are genotyped on ‘‘SNP chips.’’
Because there are many more segregating variants
in the population than those genotyped in GWASs,
it is unlikely, but not impossible, that a mutation is
genotyped itself, and so its effect usually will be de-
tected through an association with a genotyped
variant. This genotyped variant can be robustly asso-
ciated with disease in multiple samples from the
same population, or even across populations, but it
is not the mutation that causes variation in risk.
The results from GWASs have shown that variants
at many genetic loci in the genome are associated
with disease, and these also reflect many ancestral
mutations with an effect on susceptibility to disease.
Therefore, the effect size (in terms of increasing or
decreasing the absolute probability of disease) is,
on average, small, and individual variants are
neither necessary nor sufficient to cause disease.
Herein lies the problem of defining ‘‘causal’’: How
do we prove that a particular mutation causes the
observed effect on variation in the population?
Engineering the same mutation in a cell or animal
model might give a relevant phenotype, but that is
not a proof. The mutation can have a direct effect
on gene expression in human tissues or be func-
tional in another way, but that doesn’t prove it has
a causal effect on disease risk. Operationally, in this
review what we mean by ‘‘causal variant’’ is an
(unknown) variant that has a direct or indirect func-
tional effect on disease risk, rather than a variant
that is associated with disease risk through LD,
even if we don’t have the tools available at present
to prove causality beyond reasonable doubt. Hence,
it is the variant that causes the observed association
signal.in non-African populations, even though the total number
of common SNPs exceeds 10 million.7
Geneticists realized some time ago that they could
exploit population-based LD to map genes. For example,
Bodmer suggested in 1986 that fine-mapping using popu-
lation association could lead to closer linkage between
a causative mutation and a linked marker.82 However,
fine-mapping still relied on having an initial genomic loca-Thetion that is obtained from linkage analysis in family
studies. What if we do not have any prior information
on genomic loci or, alternatively, we deliberately want an
unbiased scan of the genome? In a landmark paper, Risch
and Merikangas83 showed that performing an association
scan involving one million variants in the genome and
a sample of unrelated individuals could be more powerful
than performing a linkage analysis with a few hundred
markers. It took only 10 years before this theoretical design
became reality. What was needed was the discovery (accel-
erated by the sequencing of the human genome) of
hundreds of thousands of single-nucleotide variants, the
quantification of the correlation (LD) structure of those
markers in the human genome, and the ability to accu-
rately genotype hundreds of thousands of markers in an
automated and affordable manner. The LD structure was
investigated in the HapMap project,7 and the outcome
was a list of tag SNPs that captured most of the common
genomic variation in a number of human populations.
Concurrently, commercial companies produced dense
SNP arrays that could genotype many markers in a single
assay. The technological advances together with biobanks
of either population cohorts or case-control samples facili-
tated the ability to conduct GWASs.
Although GWASs are unbiased with respect to prior bio-
logical knowledge (or prior beliefs) and with respect to
genome location, they are not unbiased in terms of what
is detectable. GWASs rely on LD between genotyped
SNPs and ungenotyped causal variants. The strength of
statistical association between alleles at two loci in the
genome strongly depends on their allele frequencies,
such that a rare variant (say, one with a frequency <0.01)
will be in low LD (as measured by r2) with a nearby
common variant, even if they map to the same recombina-
tion interval.84 But the SNPs that are on the SNP chips
have been selected to be common (most have a minor
allele frequency >0.05). Therefore, GWASs are by design
powered to detect association with causal variants that
are relatively common in the population. Is it realistic to
assume common causal variants for disease segregate in
the population? This is discussed in Box 2.
(Nearly) Five Years of Discovery
Although the first results from a GWAS were reported in
20058 and 2006,9 we take the 2007 Wellcome Trust Case
Control Consortium (WTCCC) paper in Nature10 as a start-
ing point. The reason for this is that theWTCCC study was
the first large, well-designed GWAS for complex diseases to
employ a SNP chip that had good coverage of the genome.
There are many ways to summarize the discoveries based
on GWASs in the last five years. We have tried to separate
the discoveries quantitatively and to focus on the biology.
There are nowwell over 2000 loci that are significantly and
robustly associated with one or more complex traits (see
GWAS catalog in Web Resources), as shown in Figure 1.
The vast majority of the loci identified are new, i.e., before
2007 their association with disease or other complex traitsAmerican Journal of Human Genetics 90, 7–24, January 13, 2012 9
Box 2. The CDCV Hypothesis
Currently, the allele frequency of variants that
contribute to cause common disease is a subject of
some debate.85,86 The common disease-common
variant (CDCV) hypothesis is sometimes said to be
one side of this debate; the other side holds that
disease-causing alleles are typically rare. But what
is the precise ‘‘hypothesis’’ in the CDCV hypothesis?
We tried to find the origin of the CDCV hypothesis.
Many researchers cite either Lander87 or Risch and
Merikangas.83 We will add Chakravarti88 and Reich
and Lander89 as key studies. Lander87 noted from
the then-available data that there is a limited diver-
sity in coding regions at genes, in that most variants
are very rare, and therefore the effective number of
alleles is small. In addition, he provided ‘‘tantalizing
examples’’ of common alleles with large effects (for
example, such alleles include APOE [MIM 107741],
MTHFR [MIM 607093], and ACE [MIM 106180]).
Reich and Lander89 presented a theoretical popula-
tion-genetics model that predicted a relatively
simple spectrum of the frequency of disease risk
alleles at a particular disease locus. They (re)phrased
the CDCV hypothesis as the prediction that the ex-
pected allelic identity is high for those disease loci
that are responsible for most of the population risk
for disease. These studies did not appear to make
any prediction about the number of disease loci or,
therefore, about the effect size. What the authors
stated was that if a disease was common, there was
likely to be one disease-causing allele that was
much more common than all the other disease-
causing alleles at the same locus.87,89
Risch and Merikangas83 quantified two important
points regarding the detection of disease loci: first,
that detection by association is more powerful
than linkage when the genotype-relative risk is
modest or small and the risk-allele frequency is large
(say, >10%); and second, that the multiple-testing
burden of a genome scan by association does not
prevent the detection of genome-wide-significant
findings. This paper was essentially about experi-
mental design and statistical power (and hence feasi-
bility), not about the CDCV hypothesis as such.
Finally, Chakravarti88 pointed out that if individuals
with disease needed to be homozygous for risk vari-
ants at multiple loci, then the risk alleles at those
loci must be more common than they would be in
a model in which homozygosity at any risk locus is
sufficient to cause disease. We note that without
the assumption of strong epistasis on the scale of
liability, there is no need for risk variants to be
common. For example, Risch’s multilocus multipli-
cative model,90 which implies an additive model
Box 2. Continued
on the log (risk) scale (it is one of the ‘‘exchangeable’’
models91), does not rely on a particular allelic spec-
trum of risk-allele frequencies.
What all these landmark papers have in common
is a remarkable foresight in predicting the GWAS era
well before the publication of the full draft of the
human genome sequence, the HapMap project, or
the availability of commercial genotyping. But
what can we conclude about the origin and specifics
of the CDCV hypothesis? As implicitly or explicitly
stated in these key papers, there is no strong predic-
tion about the exact allele-frequency spectrum of
risk variants in the genome, nor a prediction about
the effect size at any disease loci and hence about
the total number of risk alleles in the genome.
The current debate is about the frequency spec-
trum of disease-causing alleles. Phrasing the debate
as an either/or question is not very helpful because
examples of both common and rare alleles are
already known, but there is still an open question
as to whether most genetic variation contributing
to complex traits in the population is caused by
rare variants or common variants. A more general
question regards the spectrum of allele frequencies
of disease-causing alleles and the joint distribution
between risk-allele frequency and effect size. In the
special case of an evolutionarily neutral model and
a constant effective population size, most causal
variants that are segregating in the population will
be rare, but most heritability will be due to common
variants.79,92 The reason for this apparent paradox is
that the number of segregating variants is propor-
tional to 1/[p(1  p), where p is the allele frequency
of a risk-increasing allele (so the smaller p, the
more variants of that frequency), whereas the herita-
bility contributed at that frequency is proportional
to p(1  p). The net effect is that the heritability is
distributed equally over all frequencies, and cumula-
tively most heritability is contributed by common
variants.
10 The American Journal of Human Genetics 90, 7–24, January 13, 20was not known. Essentially, these are 2000 new biological
leads. The number of loci identified per complex trait
varies substantially, from a handful for psychiatric diseases
to a hundred or more for inflammatory bowel disease
(IBD1 [MIM 266600], including Crohn disease [CD]11
and ulcerative colitis [UC]12) and stature.13 Importantly,
the number of discovered variants is strongly correlated
with experimental sample size (Figure 2), which predicts
that an ever-increasing discovery sample size will increase
the number of discovered variants: very roughly, after
a minimum sample-size threshold below which no vari-
ants are detected is reached, a doubling in sample size leads12
Figure 1. GWAS Discoveries over Time
Data obtained from the Published GWAS Catalog (see Web
Resources). Only the top SNPs representing loci with association
p values < 5 3 108 are included, and so that multiple counting
is avoided, SNPs identified for the same traits with LD r2 > 0.8 esti-
mated from the entire HapMap samples are excluded.
Figure 2. Increase in Number of Loci Identified as a Function of
Experimental Sample Size
(A) Selected quantitative traits.
(B) Selected diseases.
The coordinates are on the log scale. The complex traits were
selected with the criteria that there were at least three GWAS
papers published on each in journals with a 2010–2011 journal
impact factor>9 (e.g.,Nature,Nature Genetics, the American Journal
of Human Genetics, and PLoS Genetics) and that at least one paper
contained more than ten genome-wide significant loci. These
traits are a representative selection among all complex traits that
fulfilled these criteria.to a doubling of the number of associated variants discov-
ered. The proportion of genetic variation explained by
significantly associated SNPs is usually low (typically less
than 10%) for many complex traits, but for diseases such
as CD and multiple sclerosis (MS [MIM 126200]), and for
quantitative traits such as height and lipid traits, between
10% and 20% of genetic variance has been accounted for
(Table 1). In comparison to the pre-GWAS era, the propor-
tion of genetic variation accounted for by newly discov-
ered variants that are segregating in the population is large.
It is clear that for most complex traits that have been
investigated by GWAS, multiple identified loci have
genome-wide statistical significance, and thus it is likely
that there are (many) other loci that have not been identi-
fied because of a lack of statistical significance (false nega-
tives). Recently, researchers have developed and applied
methods to quantify the proportion of phenotypic varia-
tion that is tagged when one considers all SNPs simulta-
neously.12–14 These methods focus on estimation rather
than hypothesis testing and do not suffer from false
negatives caused by small effect sizes.15 Whole-genome
approaches to estimating genetic variation have shown
that approximately one-third to one-half of additive
genetic variation in the population is being tagged when
all GWAS SNPs are considered simultaneously.12–14 This
is a surprisingly large proportion given that evolutionary
theory predicts that most variants affecting disease risk
ought to be found at a low frequency in the population
if they affect fitness,16,17 and such risk variants would
not be in sufficient LD with the common SNPs to be
detected in GWASs.
Autoimmune Diseases
We concentrate on seven auto-immune diseases, anky-
losing spondylitis (AS [MIM 106300]), rheumatoid arthritis
(RA [MIM 180300), systemic lupus erythematosus (SLEThe A[MIM 152700]), and type 1 diabetes (T1D [MIM 222100]),
MS, CD, and UC. Table 2 summarizes the number of genes
that have been identified for these diseases. Across these
diseases, 19 loci (mainly related to human leukocyte
antigen) were known prior to 2007, and 277 have been
discovered from 2007 onward. The total of 277 includes
multiple counts of loci that have been implicated across a
number of diseases; such loci include BLK (MIM 191305),
TNFAIP3 (MIM 191163) and CD40 (MIM 109535).
Inflammatory bowel disease (IBD, not to be confused
here with identity by descent) is thought to arise from
dysregulation of intestinal homeostasis.18 GWASs of IBD
(CD and UC) have been highly successful in terms of
the number of loci identified (99 nonoverlapping loci inmerican Journal of Human Genetics 90, 7–24, January 13, 2012 11
Table 1. Population Variation Explained by GWAS for a Selected
Number of Complex Traits
Trait or Disease
h2 Pedigree
Studies
h2 GWAS
Hitsa
h2 All
GWAS SNPsb
Type 1 diabetes 0.998 0.699 ,c 0.312
Type 2 diabetes 0.3–0.6100 0.05-0.1034
Obesity (BMI) 0.4–0.6101,102 0.01-0.0236 0.214
Crohn’s disease 0.6–0.8103 0.111 0.412
Ulcerative colitis 0.5103 0.0512
Multiple sclerosis 0.3–0.8104 0.145
Ankylosing spondylitis >0.90105 0.2106
Rheumatoid arthritis 0.6107
Schizophrenia 0.7–0.8108 0.0179 0.3109
Bipolar disorder 0.6–0.7108 0.0279 0.412
Breast cancer 0.3110 0.08111
Von Willebrand factor 0.66–0.75112,113 0.13114 0.2514
Height 0.8115,116 0.113 0.513,14
Bone mineral density 0.6-0.8117 0.05118
QT interval 0.37–0.60119,120 0.07121 0.214
HDL cholesterol 0.5122 0.157
Platelet count 0.8123 0.05–0.158
a Proportion of phenotypic variance or variance in liability explained by
genome-wide-significant and validated SNPs. For a number of diseases, other
parameters were reported, and these were converted and approximated to the
scale of total variation explained. Blank cells indicate that these parameters
have not been reported in the literature.
b Proportion of phenotypic variance or variance in liability explained when all
GWAS SNPs are considered simultaneously. Blank cell indicate that these
parameters have not been reported in the literature.
c Includes pre-GWAS loci with large effects.total18), and a substantial proportion of familial risk, about
20%, has been accounted for.11,12,18 Twenty-eight risk loci
are shared between CD and UC, despite the fact that these
diseases display distinct clinical features, and it has been
suggested that the two diseases share pathways and are
part of a mechanistic continuum.18 There are also strong
overlaps between genes involved in CD and UC, AS,19
and psoriasis (MIM 177900), again suggesting shared aetio-
pathogenic mechanisms in these conditions. Pleiotropic
genetic effects are becoming increasing widely identified,
including in classical autoimmune diseases.20 For example,
a coding variant in the gene PTPN22 (MIM 600716)
confers strong risk for T1D and RA as well as protection
against CD.18
Metabolic Diseases
In terms of metabolic diseases, we focus here specifically
on type 2 diabetes (T2D [MIM 125853]); fasting glucose
and insulin levels; body-mass index (BMI) and obesity;
and fat distribution. A recent review21 already covered
these complex traits, but we have updated that review
wherever necessary. Table 3 gives an overview of the
number of loci identified.12 The American Journal of Human Genetics 90, 7–24, January 13, 20More than 20 major GWASs for T2D have been pub-
lished to date21–24, and there has been a cumulative tally
of around 50 genome-wide-significant hits,21,23,24 only
three of which were known before the GWAS era. Most
of these studies have involved individuals of European
descent; the latest published effort is from the DIAGRAM
(Diabetes Genetics Replication and Meta-analysis)
Consortium and includes more than 47,000 GWAS indi-
viduals and 94,000 samples for replication. More recently,
equivalent studies have emerged from samples of East
Asians,23,25–27 South Asians,22 and Hispanics,28,29 and
large studies involving African Americans and other major
ethnic groups are underway. Notwithstanding differences
in allele frequency and LD patterns, most of the signals
found in one ethnic group show some evidence of associ-
ation in others, indicating that the common-variant
signals identified by GWASs are likely to be the result of
widely distributed causal alleles that are of relatively high
frequency. This is an important observation because it
indicates that most of the GWAS-identified associations
for T2D reflect high LD with a causal variant that has
a small effect size rather than low LD with a causal variant
that has a large effect size. The largest common-variant
signal identified for T2D remains TCF7L2 (MIM 602228)
(detected just prior to the GWAS era30), which has a
per-allele odss ratio (OR) of around 1.35. The remaining
signals detected by GWAS have allelic ORs in the range
between 1.05 and 1.25. Collectively, the most-strongly
associated variants at these loci are estimated to explain
around 10% of familial aggregation of T2D in European
populations.
The MAGIC (Meta-Analysis of Glucose- and Insulin-
Related Traits Consortium) investigators have been
carrying out equivalent analyses focused on the identifica-
tion of variants influencing variation in glucose and
insulin levels in healthy nondiabetic individuals.31–33 Prior
to the GWAS era, the only compelling association signal
for fasting glucose levels was known at GCK (MIM
138079) (glucokinase),34 but GWAS in European samples
(46,000 GWAS and 76,000 replication samples) have
expanded that number to 1632. These variants explain
around 10% of the inherited variation in fasting glucose
levels. Only two signals (near GCKR [MIM 600842] and
IGF1 [MIM 147440]) were shown to influence fasting
insulin levels in the same analysis. Equivalent analyses
for 2h glucose33 (15,000 GWAS samples and up to 30,000
replication samples) identified further signals, including
variants near the GIP (MIM 137240) receptor (GIPR [MIM
137241]).
Before the GWAS era, the only robust association
between DNA sequence variation and either BMI or
weight involved low-frequency variants in MC4R (MIM
155541).35 Now, there are more than 30. In the most
recent study from the GIANT consortium,36 these analyses
extended to almost 250,000 samples, half of them in the
stage 1 GWAS, the remainder for replication. The largest
signal remains that at FTO (MIM 610966),37 where the12
Table 2. Summary of GWAS Findings for Seven Autoimmune Diseasesa
Prior to 2007 2007 onward
Disease Number of Loci Loci Number of Loci Some or All of the Loci
Ankylosing
spondylitis
1 HLA-B27 13 IL23R, ERAP1, 2p15, 21q22, CARD9 (MIM 607212), IL12B
(MIM 161561), PTGER4 (MIM 601586), IL1R2 (MIM 147811),
TNFR1, TBKBP1 (MIM 608476), ANTXR2 (MIM 608041),
RUNX3 (MIM 600210), KIF21B (MIM 608322)
Rheumatoid
arthritis
3 HLA-DRB1,
PADI4,
CTLA4
30 AFF3 (MIM 601464), BLK, CCL21 (MIM 602737), CD2/CD58
(MIM 186990)/153420], CD28, CD40, FCGR2A (MIM 146790),
HLA-DRB1, IL2/IL21 (MIM 147680/605384), IL2RA, IL2RB
(MIM 146710), KIF5A/PIP4K2C, PRDM1 (MIM 603423), PRKCQ
(MIM 600448), PTPRC (MIM 151460), REL (MIM 164910), STAT4
(MIM 600558), TAGAP, TNFAIP3, TNFRSF14, TRAF1/C5 (MIM
120900/601711), TRAF6 (MIM 602355), IL6ST (MIM 600694),
SPRED2 (MIM 609292), RBPJ (MIM 147183), CCR6
(MIM 601835), IRF5 (MIM 607218), PXK (MIM 611450)
Systemic lupus
erythematosus
3 HLA, PTPN22,
IRF5 (MIM
607218)
31 BANK1 (MIM 610292), BLK (MIM 191305), C1q, C2 (MIM 613927),
C4A/B (MIM 120820/120810), CRP (MIM 123260), ETS1
(MIM 164720), FcGR2A–FcGR3A (MIM 146790/146740), FcGR3B
(MIM 610665), HIC2-UBE2L3 (MIM 607712/603721), IKZF1 (MIM
603023), IL10 (MIM 124092), IRAK1 (MIM 300283), ITGAM–ITGAX
(MIM 120980)/151510], JAZF1, KIAA1542/PHRF1, LRRC18-WDFY4,
LYN (MIM 165120), NMNAT2 (MIM 608701), PRDM1 (MIM
603423), PTTG1 (MIM 604147), PXK (MIM 611450), RASGRP3
(MIM 609531), SLC15A4, STAT1 (MIM 600555), TNFAIP3, TNFSF4
(MIM 603594), TNIP1 (MIM 607714), TREX1 (MIM 606609),
UHRF1BP1, XKR6
Type 1
diabetes
4 HLA, INS
(MIM 176730),
PTPN22, CTLA4
40 RGS1, IL18RAP (MIM 604509), IFIH1 (MIM 606951), CCR5 (MIM
601373), IL2 (MIM 147680), IL7R, MHC, BACH2 (MIM 605394),
TNFAIP3, TAGAP, IL2RA, PRKCQ (MIM 600448), INS (MIM 176730),
ERBB3 (MIM 190151), 12q13.3, SH2B3 (MIM 605093), CTSH
(MIM 116820), CLEC16A (MIM 611303), PTPN2 (MIM 176887),
CD226 (MIM 605397), UBASH3A (MIM 605736), C1QTNF6, IL10
(MIM 124092), 4p15.2, C6orf173, 7p15.2, COBL (MIM 610317),
GLIS3 (MIM 610192), C10orf59, CD69 (MIM 107273), 14q24.1,
14q32.2, IL27 (MIM 608273), 16q23.1, ORMDL3 (MIM 610075),
17q21.2, 19q13.32, 20p13, 22q12.2, Xq28
Multiple
sclerosis
1 HLA 52 BACH2 (MIM 605394), BATF (MIM 612476), CBLB, CD40, CD58,
CD6 (MIM 186720), CD86, CLEC16A (MIM 611303), CLECL1,
CYP24A1, CYP27B1, DKKL1 (MIM 605418), EOMES (MIM 604615),
EVI5 (MIM 602942), GALC (MIM 606890), HHEX (MIM 604420),
IL12A, IL12B, IL22RA2, IL2RA, IL7, IL7R, IRF8, KIF21B (MIM
608322), MALT1, MAPK1 (MIM 176948), MERTK (MIM 604705),
MMEL1,MPHOSPH9 (MIM 605501),MPV17L2,MYB (MIM 189990),
MYC (MIM 190080), OLIG3 (MIM 609323), PLEK (MIM 173570),
PTGER4 (MIM 601586), PVT1 (MIM 165140), RGS1, SCO2 (MIM
604272), SP140 (MIM 608602), STAT3, TAGAP, THEMIS (MIM
613607), TMEM39A, TNFRSF1A, TNFSF14 (MIM 604520), TYK2,
VCAM1, ZFP36L1 (MIM 601064), ZMIZ1 (MIM 607159), ZNF767
Crohn’s
disease
4 NOD2 (MIM 605956),
IBD5 (MIM 606348),
DRB1*0103, IL23R
67 SMAD3 (MIM 603109), ERAP2 (MIM 609497), IL10 (MIM 124092),
IL2RA, TYK2, FUT2 (MIM 182100), DNMT3A (MIM 602769),
DENND1B (MIM 613292), BACH2 (MIM 605394), ATG16L1
(MIM 610767)
Ulcerative
colitis
3 DRB1*1502,
DRB1*0103, IL23R
44 IL1R2 (MIM 147811), IL8RA-IL8RB, IL7R, IL12B, DAP
(MIM 600954), PRDM1 (MIM 603423), JAK2 (MIM 147796),
IRF5 (MIM 607218), GNA12 (MIM 604394), LSP1 (MIM 153432),
ATG16L1 (MIM 610767)
Total 19 277
a The names of the loci are signposts and do not indicate that these loci are necessarily biologically relevant. A number of associated variants are distant from
protein-coding genes.average between-homozygotes difference in weight is
around 2.5 kg. The effects at other loci are smaller, and
in combination, these variants explain no more than
1%–2% of overall variation in adult BMI (although this
percentage rises to almost 20% if the analysis is extended
to all GWA variants, not just those that reach genome-The Awide significance14). As well as these studies of BMI and
obesity in population samples, there have been several
studies focused on extreme obesity phenotypes.38,39 The
genome-wide-significant loci thrown up by these efforts
only partially overlap with those emerging from popula-
tion-based studies, raising the possibility that some ofmerican Journal of Human Genetics 90, 7–24, January 13, 2012 13
Table 3. Summary of GWAS Findings for Metabolic Traitsa
Prior to 2007 2007 onward
Disease Number of Loci Loci Number of Loci Some or All of the Loci
Type 2 diabetes 3 PPARG, KCNJ11
(MIM 600937),
TCF7L2
50 NOTCH2 (MIM 600275), PROX1 (MIM 601546), GCKR, THADA
(MIM 611800), BCL11A (MIM 606557), RBMS1 (MIM 602310), IRS1,
ADAMTS9, ADCY5 (MIM 600293), IGF2BP2 (MIM 608289), WFS1,
ZBED3, CDKAL1, DGKB (MIM 604070), JAZF1, GCK, KLF14,
TP53INP1 (MIM 606185), SLC30A8 (MIM 611145), PTPRD
(MIM 601598), CDKN2A, CHCHD9, CDC123,HHEX (MIM 604420),
DUSP8 (MIM 602038), KCNQ1, CENTD2, MTNR1B, HMGA2 (MIM
600698), TSPAN8 (MIM 600769), HNF1A, ZFAND6 (MIM 610183),
PRC1 (MIM 603484), FTO, SRR (MIM 606477), HNF1B (MIM
189907), DUSP9 (MIM 300134), CDCD4A, UBE2E2 (MIM 602163),
GRB14 (MIM 601524), ST6GAL1 (MIM 109675), VPS26A (MIM
605506), HMG20A (MIM 605534), AP3S2 (MIM 602416), HNF4A
(MIM 600281), SPRY2 (MIM 602466)
Body-mass index 1 MC4R 30 NEGR1 (MIM 613173), TNNI3K (MIM 613932), PTBP2 (MIM
608449), TMEM18 (MIM 613220), POMC, FANCL (MIM 608111),
LRP1B (MIM 608766), CADM2 (MIM 609938), ETV5 (MIM 601600),
GNPDA2 (MIM 613222), SLC39A8 (MIM 608732), HMGCR
(MIM 142910), PCSK1, ZNF608, NCR3 (MIM 611550), HMGA1
(MIM 600701), LRRN6C, TUB (MIM 601197), BDNF, MTCH2
(MIM 613221), FAIM3 (MIM 606015), MTIF3, PRKD1
(MIM 605435), MAP2K5 (MIM 602520), FTO, SH2B1, GPRC5B
(MIM 605948), KCTD15, GIPR, TMEM160
Glucose or insulin 1 GCK 15 GCKR, G6PC2, IGF1, ADCY5 (MIM 600293), MADD (MIM 603584),
ADRA2A, CRY2 (MIM 603732), FADS1 (MIM 606148), GLIS3
(MIM 610192), SLC2A2, PROX1 (MIM 601546), C2CD4B (MIM
610344), DGKB (MIM 604070), GIPR, VPS13C (MIM 608879)
Fat distribution 0 20 TBX15 (MIM 604127), LYPLAL1, IRS1, SPRY2 (MIM 602466), GRB14
(MIM 601524), STAB1 (MIM 608560), ADAMTS9, CPEB4 (MIM
610607), VEGFA (MIM 192240), TFAP2B (MIM 601601), LY86
(MIM 605241), RSPO3 (MIM 610574),NFE2L3 (MIM 604135),MSRA
(MIM 601250), ITPR2 (MIM 600144), HOXC13 (MIM 142976),
NRXN3 (MIM 600567), ZNRF3 (MIM 612062), PIGC (MIM 601730)
Total 5 107
a The names of the loci are signposts and do not indicate that these loci are necessarily biologically relevant. A number of associated variants are distant from
protein-coding genes.the most extreme cases of obesity are driven by highly
penetrant, low-frequency variants. Variation at copy-
number variants (CNVs) has some impact on BMI. This is
true of commonCNVs (theNEGR1 association seems likely
to be driven by a common CNV40) and also rarer CNVs for
which evidence is starting to accumulate (e.g., 16p CNV
and effect on morbid obesity and developmental delay41).
The adverse metabolic effects of obesity depend not
only on the overall level of adiposity but also on the distribu-
tion of fat around the body; visceral (abdominal) fat has
particularly adverse consequences for overall health. GWASs
of fat-distribution phenotypes (including waist circumfer-
ence,waist:hipratio, andbody-fatpercentage studied inclose
to 200,000 individuals) have revealed almost 20 loci with
genome-wide significance40,42–44 and relatively little overlap
with those loci influencingoverall adiposity.AswithBMI, the
proportion of variance explained by these loci is small
(around 1% after adjustment for BMI, age, and sex).
New Biology Arising from GWAS Discoveries
Autoimmune Diseases
Thus far nearly all genes associated with MS have been
involved in autoimmune pathways rather than in14 The American Journal of Human Genetics 90, 7–24, January 13, 20neurologic degenerative diseases.45 Indeed, of the two
MS-associated genes involved in neurodegeneration, one
(KIF21B) is also associated with AS and CD, suggesting
that it is actually an autoimmunity gene. The genes
involved in MS include genes coding for components of
the cytokine pathway (CXCR5 [MIM 601613], IL2RA
[MIM 147730], IL7R [MIM 146661], IL7 [MIM 146660],
IL12RB1 [MIM 601604], IL22RA2 [MIM 606648], IL12A
[MIM 161560], IL12B [MIM 161561], IRF8 [MIM 601565],
TNFRSF1A [MIM 191190], TNFRSF14 [MIM 602746], and
TNFSF14 [MIM 604520]), costimulatory molecules
(CD37 [MIM 151523], CD40, CD58 [MIM 153420],
CD80 [MIM 112203], CD86 [MIM 601020], and CLECL1
[MIM 607467]), and signal-transduction molecules of
immunological relevance (CBLB [MIM 604491], GPR65
[MIM 604620], MALT1 [MIM 604860], RGS1 [MIM
600323], STAT3 [MIM 102582], TAGAP [MIM 609667],
andTYK2 [MIM176941]). Interestingly, these genesmainly
implicate T-helper cells in MS pathogenesis.
Genetic findings have had amajor impact on AS research
and therapeutics. The association of the genes IL23R (MIM
607562)46 and IL12B19 have pointed to the involvement of
the IL-23R pathway, and hence IL-17-producing12
proinflammatory cell populations, in the aetiopathogene-
sis of AS. The involvement of this pathway in AS was not
considered until the genetic discoveries were reported.
The recent demonstration that ERAP1 (MIM 606832) poly-
morphisms are associated with HLA-B27-positive but not
HLA-B27-negative AS has shed important light on research
into the mechanism by which HLA-B27 induces AS; this
mechanism has remained an enigma since the discovery
of the association of HLA-B27 with AS in the early 1970s.
ERAP1 is involved in peptide processing before HLA class
I molecule presentation; the restriction of the association
of ERAP1 variants to HLA-B27-positive disease indicates
that HLA-B27 operates to cause AS by a mechanism
that involves peptide presentation. Protective variants of
ERAP1 have been shown to have lower peptide-processing
capacity and thus to reduce the amount of peptide avail-
able to HLA-B27.47 Thus HLA-B27 is more likely to cause
AS when it is processing more peptides.
The finding that PADI4 (MIM 605347) is associated with
RA focused research interest on the role of anti-citrulli-
nated peptide antibodies (ACPAs) and disease.48 PADI4 is
involved in the citrullination of peptides against which
ACPAs develop. The association of PADI4 variants with
RA therefore indicated that ACPAs are directly involved
in RA pathogenesis, not an indirect manifestation of
immune dysregulation in the disease. Subsequently, it
was discovered that the association of HLA-DRB1 (MIM
142857) with RA was restricted to ACPA-positive disease
and that there was a strong gene-environment interaction,
such that cigarette smoking increases the risk of ACPA-
positive but not ACPA-negative RA.49 Because ACPA-
positive disease is more severe than ACPA-negative disease
and has a greater propensity toward joint-damaging
erosion, this provided further evidence supporting public-
health measures against cigarette smoking.
The genetic loci identified for IBD through GWASs have
highlighted a number of pathways, including antibacterial
autophagy and signaling pathways (e.g., IL-10 signaling,
T-cell-negative regulators, and pathways involving B cells
and innate sensors).18 Some of these pathways were previ-
ously not suspected to be important for these diseases.
The role of a number of pathways, for example the IL-23R
pathway, the autophagy pathway, and innate immunity,
haveall come fromhypothesis-generatinggenetics research,
not from immunology or hypothesis-driven research.
Similar advances could be described for many other
autoimmune diseases but are beyond the scope of this
review.
Metabolic Traits
Most loci affecting T2D and fasting glucose levels map to
regulatory sequences, and inmany cases, the ‘‘causal’’ tran-
script, i.e., the transcript responsible for mediating the
effect of the associated variants, is not yet known. At other
loci, a combination of coding variants, strong biological
candidates, and/or cis expression QTL data has defined
the transcript through which the effect is mediatedThe A(HNF1A [MIM 142410], GCK, IRS1 [MIM 147545], WFS1
[MIM 606201], PPARG [MIM 601487], CAMK1D [MIM
607957], JAZF1 [MIM 606246], KLF14 [MIM 609393] and
others) as a first step to inferring biology.50 Some of these
stories are now starting to be fleshed out into biological
mechanisms (e.g., KLF1451).
There is incomplete overlap with the loci influencing
physiological variation in glucose and insulin. Some loci
(e.g.,MTNR1B [MIM 600804]) have a relatively large effect
on both, whereas others (e.g., G6PC2 [MIM 608058])
influence fasting glucose levels but have a minimal effect
on T2D risk. Still others (e.g., CDKN2A and CDKN2 B
[MIM 600160 and 600431]) impact T2D and have surpris-
ingly modest effects on fasting glucose levels in healthy,
nondiabetic individuals32,33,50. Most of these loci appear
to have their primary effect on the function of beta cells
rather than on insulin resistance, highlighting the impor-
tance of the former with respect to normal and abnormal
glucose homeostasis.50 Of the subset of loci (including
PPARG, KLF14, and ADAMTS9 [MIM 605421]) shown to
influence T2D risk through a primary effect on insulin
resistance, only FTO seems to act primarily through an
effect on obesity.50 Several of the T2D loci overlap genes
that are known to harbor rare variants responsible for
penetrant, monogenic forms of diabetes (such genes
include KCNQ1 [MIM 607542], PPARG, HNF1A, GCK,
and WFS1), indicating that multiple causal variants at
the same locus segregate in the population at difference
frequencies. There is overlap between signals influencing
T2D risk and those influencing body weight (CDKAL1
[MIM 611259] and ADCY5 [MIM 600293]) indicating
that some of the observed epidemiological associations
between these traits are attributable to shared suscepti-
bility variants.52
Whereas many of the fasting-glucose and fasting-insulin
signals map near strong biological candidates for relevant
traits (such candidate genes include IRS1, IGF1, ADRA2A
[MIM 104210], SLC2A2 [MIM 138160], GCK and GCKR)
and fit within established models of our understanding
of islet biology, this is far from the case with the loci iden-
tified for T2D. Efforts to demonstrate that the genes
mapping close to T2D risk loci are enriched for particular
pathways or processes have met with only limited success;
the most robust finding yet has been in relation to
cell-cycle regulation (and was consistent with a model in
which the regulation of islet mass is a key component of
risk50). Either T2D is especially heterogeneous or else key
aspects of its pathophysiology are as yet poorly codified
in existing databases.
As for T2D and fasting glucose, most of the signals for
obesity and fat distribution map to regulatory signals, the
causal transcript is known at only a minority of the loci.
Signals influencing BMI appear to be enriched for genes
implicated in neuronal processes, whereas those influ-
encing fat distribution seem to be more closely related to
adipose development.36,43 Overlap with signals and genes
implicated inmore severe forms of disease (morbid obesity,merican Journal of Human Genetics 90, 7–24, January 13, 2012 15
lipodystrophy) is seen at some loci (PCSK1 [MIM 162150],
POMC [MIM 176830], BDNF [MIM 113505], MC4R, and
SH2B1 [MIM 608937]) but is far from complete (some
loci implicated in extreme obesity case-control studies
show no association with BMI at the population level36).
The strongest signal for overall adiposityis the one map-
ping to FTO37. FTO is thought to be a DNA methylase,53
but its function is poorly understood. Murine models
demonstrate that modulation of Fto expression is associ-
ated with changes in body weight,54–56 but no direct
evidence linking coding variants in FTO in humans to
body-weight variation has been demonstrated. For the
time being, FTO remains the strongest candidate, but
the role of other genes (e.g., RPGRIP1L [MIM 610937]) in
the region cannot be discounted. This example demon-
strates the difficulties that remain in relating GWAS signals
to downstream biology. Fat distribution is a strongly
gender-dimorphic phenotype, and many of the signals
associated with fat distribution seem to have a selective
effect on this phenotype in women.43
Quantitative Traits
In addition to having been performed on the quantitative
traits discussed previously (e.g., BMI and fasting-glucose
and -insulin levels), GWASs have been done on a number
of quantitative risk factors for disease and for traits that
are models for the genetic architecture of complex traits.
For bone mineral density (BMD), a risk factor for osteopo-
rotic fracture, a total of 34 loci, together explaining ~5% of
narrow sense heritability, have been identified (Estrada
et al., abstract presented at the American Society for Bone
and Mineral Research 2010 Annual Meeting, published
in J. Bone. Med. Res. 25 [Suppl S1], p. 1243). Among these
genes, there is a major over-representation of genes in the
Wnt-signaling pathway, which was first implicated in oste-
oporosis (MIM 166710) from studies in families with high
or low BMD phenotypes. Many other examples exist in
osteoporosis and other human diseases in which GWASs
have demonstrated that more-prevalent but less-severe
genetic variants in genes initially identified from studies
of severe familial diseases have proven to be important in
the risk of disease in the general population. For human
height, a combined discovery and validation cohort of
~180,000 samples identified 180 robustly associated loci,
many in meaningful biological pathways and with evi-
dence for multiple segregating variants at the same loci.13
Together these loci explain approximately 12%–14% of
additive genetic variation (~10% of phenotypic variation).
A meta-analysis of more than 100,000 individuals of
European ancestry detected a total of 95 loci significantly
associated with plasma concentrations of cholesterol
and triglycerides, known risk factors for coronary artery
disease,57 and it provided evidence that the GWAS loci
were of biological and clinical relevance. A meta-analysis
from the HaemGen consortium on platelet count and
platelet volume, which are endophenotypes for myo-
cardial infarction (MIM 608446), discovered 68 loci.5816 The American Journal of Human Genetics 90, 7–24, January 13, 20When the genes of a number of these loci were silenced
in Drosophila, 11 showed a clear platelet phenotype. These
genes are previously unknown regulators of blood cell
formation. The identification of so many loci has uncov-
ered new gene functions in megakaryopoiesis and platelet
formation. That is, new biology has resulted directly from
the identification of SNPs that are associated with variation
in platelet phenotypes.
Across these quantitative traits, a number of loci discov-
ered through GWASs were known to be a mutational target
for those traits because Mendelian forms with extreme
phenotypes existed. Taken together, the inference from
quantitative traits in terms of the (large) number of loci
involved, the allelic frequency spectrum of associated vari-
ants, and the nature of the candidate genes suggest that
models arising from quantitative traits appropriately
reflect the genetic architecture of disease and reinforce
the emerging evidence that it is the cumulative effect of
many loci that underlies susceptibility to disease.
From GWAS to Translation: Clinical Relevance
Autoimmune Diseases
Many of the MS-associated genes discovered by GWASs
represent excellent potential therapeutic targets. Of partic-
ular note is the identification of two genes involved in
vitamin D metabolism (CYP27B1 [MIM 609506] and
CYP24A1 [MIM 126065]). This identification might help
to explain the latitudinal variation in MS incidence—i.e.,
higher MS prevalence at more extreme latitudes is most
likely due to higher rates of vitamin D deficiency. Two
other identified genes are already targets of MS therapies,
highlighting the relevance of the findings to the disease
pathogenesis (natalizumab targets VCAM1 [MIM
192225], and daclizumab targets IL2RA). The findings for
AS have stimulated the trial of therapies against identified
pathways. Anti-IL-17 treatment has been shown in a phase
2 trial to have equivalent efficacy as the current gold-stan-
dard treatment, TNF-inhibition, in the treatment of AS.
The relevance of the RA-related genetic findings to thera-
peutic development is highlighted by the fact that some
existing therapies already target genes or gene pathways
highlighted by the genetic associations with RA; such ther-
apies include those involving TNF inhibitors (e.g., inflixi-
mab) and co-stimulation inhibitors (e.g., abatacept).
Abatacept is a fusion protein of CTLA-4 and immunoglob-
ulin. It acts by preventing costimulation of T-helper cells
by the binding of the T cell’s CD28 protein to the B7
protein on the antigen-presenting cell. CTLA4 (MIM
123890) and CD28 (MIM 186760) polymorphisms are
associated with RA. The RA-associated genes include
many involved in the NfKB signaling pathway and
place this pathway at the center of RA pathogenesis. As
in MS, mouse research prior to the genetic discoveries
had implicated the IL-23-dependent Th17-lymphocyte
pathway in RA pathogenesis. To date there has been very
little genetic support for this with regard to human
diseases, in contrast to the situation in seronegative12
diseases such as AS, psoriasis and IBD, where strong genetic
associations exist and treatments targeting the pathway
are in clinical use.
Metabolic Diseases
The main relevance of GWASs lies in the insights into
disease biology (see above) and the potential for clinical
translation through novel approaches to the diagnosis,
prevention, treatment, and monitoring of disease. This
will take some time, in particular given that most GWAS
discoveries were made in the last few years. The predictive
power of disease risk ascertained from genetic data remains
poor because for most diseases only a small proportion of
additive genetic variation has been accounted for.
Although it is possible for T2D to identify individuals
who are at the extremes of the genotype risk score distribu-
tion and who differ appreciably in T2D risk (they have
twice or half the average risk for the upper and lower
1%–2%, respectively), many of these would already be
identifiable on the basis of classical risk factors. In fact,
when using receiver operating characteristic (ROC) anal-
yses, BMI and age do a far better job of discrimination
than the genetic variants so far discovered.59 This may
change as low frequency and rare causal alleles are found.
Although individual prediction is not yet practical with
the variants at hand, it should be possible to identify
groups of individuals who are at a substantially greater-
than-average risk for diabetes, and this might be of value,
for example, with respect to clinical-trial enrichment.
One obvious route to early translation involves the iden-
tification of diagnostic biomarkers on the basis of the
processes that have been uncovered. These may have
predictive impact well beyond the genetic variants that
led to their discovery. This was recently demonstrated by
a GWAS of C-reactive protein (CRP) levels; that study
found that common variants near the HNF1A gene were
associated with variation in CRP.60 The authors asked
whether rare HNF1A mutations that are causal for the
Mendelian MODY (MIM 606391) subtype of diabetes are
also associated with differences in CRP levels and whether
it would be possible to use CRP levels as a diagnostic
marker to help identify individuals who have early-onset
diabetes and who are likely to have HNF1A-MODY (and
to direct those individuals to sequence-based diagnostics).
They were able to show marked differences in CRP levels
between HNF1A -MODY and other types of diabetes and
demonstrated that diagnoses based on CRP levels has
a discriminative accuracy of more than 80% for this diag-
nostic classification.61,62 Otherwise, GWAS findings have
as yet had no impact on therapeutic optimization. Recent
studies have identified variants that influence therapeutic
response to metformin63 and might herald better under-
standing of how these drugs work.
New Science Facilitated by GWASs
Although the GWAS approach was designed for the detec-
tion of associations between DNA markers and disease, asThe Aa by-product such studies have generated new scientific
discoveries. A detailed description and discussion is outside
the scope of this review, and we highlight only a few of
these advances: the discovery of genes affecting genetic
recombination and their correlation with natural selec-
tion64–66 and new insight in human population structure
and evolution.67–73
Interpretation of GWAS Results
GWASs conducted in the last five years were designed and
powered to detect associations through LD between geno-
typed (or imputed) common SNP markers and unknown
causal variants. What do the results imply in terms of vari-
ance explained in the population, common versus rare
variants underlying complex traits, and the nature of
complex-trait variation and evolution? It is too early to
be able to quantify the joint distribution of risk-allele
frequencies and their effect sizes because there are very
few causal variants identified by GWAS and because
systematic study of rare variants (through exome or
whole-genome sequencing) is in an early stage. To under-
stand the allelic spectrum of risk variants and thereby
inform optimal design of experiments aiming to detect
causal variants, one must differentiate between two expla-
nations for observed associations between genotyped
common SNPs and disease: the association can be caused
by one or more causal variants that have large effect sizes
and are in low LD with the genotyped SNPs, or it can be
caused by causal variants that have small effects and are
in high LD with the genotyped SNPs. Low LD occurs
when the allele frequencies of the unknown causal vari-
ants and those at the genotyped SNPs are very different
from each other, for example when the allele frequency
of causal variants is much lower than that of the SNPs.
For a single robustly associated SNP in a homogeneous
population, we cannot distinguish between the hypoth-
eses that the association signal is caused by a rare variant
of large effect or a common variant with small effect.
However, variants at multiple loci and GWASs in other
ethnic populations help to narrow the boundaries of the
genetic architecture of diseases. At this point in time, we
can conclude that
(1) Many loci contribute to complex-trait variation
(e.g., Figure 2).
(2) At a number of identified risk loci, there aremultiple
alleles associated with disease at a wide range of
frequencies.
(3) There is evidence for pleiotropy, i.e., that the same
variants are associated with multiple traits.66,74,75
(4) A number of variants associated with disease or
complex traits in one ethnic population are also
associated the same disease or traits in other popula-
tions (see above for T2D examples).
(5) The hypothesis76 that causal variant(s) that lead to
the association between common SNPs and disease
are mostly rare (say, have an allele frequency of 1%merican Journal of Human Genetics 90, 7–24, January 13, 2012 17
Box 3. Synthetic Associations
Dickson and colleagues suggested that the observed
association between a common SNP and a complex
trait might result when one or more rare variants at
the locus is in LD with that SNP.76,93 Because
common SNP alleles and rare causal variants cannot
be highly correlated because of the properties of
LD,84 the hypothesis of ‘‘synthetic’’ associations
implies that the effect sizes of the causal variants
are much larger than the effect size observed at the
common SNP and suggests that (re)sequencing
studies might detect such variants. The hypothesis
is not about whether GWASs work as an experi-
mental design but what the likely interpretation of
GWAS hits is in terms of the allele spectrum of causal
risk alleles. Are empirical data consistent with this
hypothesis? Several lines of evidence suggest that
associations observed with common SNP associa-
tions are rarely due to synthetic associations with
rare variants. First, because the LD correlation
between common and rare variants is so low (typi-
cally 0.01–0.02), synthetic associations imply that
variation explained by the causal variants at the
locus is 50–100 times larger than the variance ex-
plained at the genotyped SNP.78 So, if the SNP
explains 0.1% of phenotypic variation in the popu-
lation, the causal variant would explain 5%–10%.
But as shown in this review, for many complex traits
and diseases tens to hundred of common variants
are identified, and so their combined effects would
explain too much variation if synthetic associations
were the norm. Second, empirical data from
(re)sequencing studies and trans-ethnic mapping
suggest that both common and rare variants
contribute to disease risk.77 At most loci detected
by GWASs, there is no evidence (despite extensive
genotyping and/or re-sequencing) that the
common-variant signal is driven by low-frequency
or rarer variants. Where rare risk alleles are uncov-
ered at the same loci, they seem much more likely
to be independent signals.94–96
Together these observations point to a highly
polygenic model of disease susceptibility with causal
variants across the entire range of the allele-
frequency spectrum. By ‘‘polygenic,’’ we mean that
segregating variants at many genomic loci (tens,
hundreds, or even thousands) contribute to genetic
variation for susceptibility in the population. The
observations imply that, for most common complex
diseases, nearly everyone in the population carries
some risk alleles and that affected individuals are
likely to have a different portfolio of risk alleles.79
They also imply that any single risk allele is neither
necessary nor sufficient to cause disease. For the
Box 3. Continued
etiology of disease, these observations provide
empirical evidence to support a threshold or burden
model involving multiple variants and environ-
mental factors, and they appear to be inconsistent
with a single cause (e.g., a single mutation). A rare-
variant only model of disease, characterized by locus
heterogeneity and raremutations of large effects and
proposed by, for example, McClellan and King,1 is
not consistent with empirical observations.77,79,97
18 The American Journal of Human Genetics 90, 7–24, January 13, 2012or lower) isnot consistentwith theoretical and empir-
ical results.77,78 In particular, there is no widespread
evidence for the existence of ‘‘synthetic associations’’
(see Box 3). Numerically, we expect that most causal
variants that segregate in the population are rare,
consistent with evolutionary theory, but the propor-
tion of genetic variation that these variants cumula-
tively explain depends on their correlation with
fitness.79
(6) A surprisingly large proportion of additive genetic
variation is tagged when all SNPs are considered
simultaneously.12–14The Cost of GWASs
If we assume that the GWAS results from Figure 1 represent
a total of 500,000 SNP chips and that on average a chip
costs $500, then this is a total investment of $250 million.
If there are a total of ~2,000 loci detected across all traits,
then this implies an investment of $125,000 per discov-
ered locus. Is that a good investment? We think so: The
total amount of money spent on candidate-gene studies
and linkage analyses in the 1990s and 2000s probably
exceeds $250M, and they in total have had little to show
for it. Also, it is worthwhile to put these amounts in
context. $250M is of the order of the cost of a one-two
stealth fighter jets and much less than the cost of a single
navy submarine. It is a fraction of the ~$9 billion cost of
the Large Hadron Collider. It would also pay for about
100 R01 grants. Would those 100 non-funded R01 grants
have made breakthrough discoveries in biology and medi-
cine? We simply can’t answer this question, but we can
conclude that a tremendous number of genuinely new
discoveries have been made in a period of only five years.
Concluding Comments
In this review we have attempted to summarize the
tremendous quality and quantity of discoveries that have
been made by GWASs in the last five years. Because of
space limitations, we have been able to discuss only
a subset of diseases and have not mentioned those made
in common cancers, pediatric diseases, and ophthalmolog-
ical diseases, to name but a few. We now return to the
perceived failure of GWASs as summarized in the introduc-
tory section:
(1) Is the GWAS approach founded on a flawed assumption
that genetics plays an important role in the risk for
common diseases? Pedigree studies, including those
involving twins, suggest that a substantial propor-
tion of variation in susceptibility for common
disease is due to genetic factors. The proportion of
total variation explained by genome-wide-signifi-
cant variants has reached 10%–20% for a number
of diseases, and clearly there are additional variants
with such small effect sizes that they have not been
detected with stringent significance. As reviewed
here, many of the detected loci are in biologically
meaningful pathways for the diseases investigated.
Whole-genome analyses involving GWAS data
have estimated that 20%–50% of phenotypic varia-
tion is captured when all SNPs are considered simul-
taneously for a number of complex diseases and
traits. These estimates are based on population-
wide studies and provide a lower limit of the total
proportion of phenotypic variation due to genetic
factors. Inference from GWASs is independent of
inference drawn from close relatives (pedigree/
family studies), and therefore these studies have
provided independent evidence for the role of
genetics in common diseases.
(2) Have GWASs been disappointing in not explaining more
genetic variation in the population? This criticism
implies that the aim of GWASs is to explain all
genetic variation. This is a misrepresentation of
the objective of GWASs. As was the aim of linkage
studies in pedigrees for complex diseases prior to
the GWAS era, the aim of GWAS is to detect loci
that are associated with complex traits. The detec-
tion of such loci has led to the discovery of new bio-
logical knowledge about disease—knowledge that
was absent only five years ago. But even ignoring
the aim of GWASs, for a number of complex traits
the proportion of genetic variation uncovered by
GWASs is actually substantial. For example, for
T2D, MS, and CD, approximately 10%, 20%, and
20%, respectively, of genetic variation in the popu-
lation has been accounted for. Apart from diseases
with a known major locus (which is usually the
major histocompatibility locus), the baseline of
variation explained five years ago was essentially
zero.
(3) Have GWASs delivered meaningful biologically relevant
knowledge or results of clinical or any other utility? As
we have highlighted in this review, the answer to
this question is a definite ‘‘yes.’’ For example, the
discovery of the importance of the autophagy
pathway in Crohn disease, the IL-23R pathway in
rheumatoid arthritis, and factor H in age-related
macular degeneration (MIM 610149)9 have givenThe Aimportant biological insight with direct clinical
relevance. Hunter and Kraft put it this way back in
2007: ‘‘There have been few, if any, similar bursts
of discovery in the history of medical research.’’80
(4) Are GWAS results spurious? The combination of large
sample sizes and stringent significance testing has
led to a large number of robust and replicable asso-
ciations between complex traits and genetic vari-
ants, many of which are in meaningful biological
pathways. A number of variants or different variants
at the same loci have been shown to be associated
with the same trait in different ethnic populations,
and some loci are even replicated across species.81
The combination of multiple variants with small
effect sizes has been shown to predict disease status
or phenotype in independent samples from the
same population. Clearly, these results are not
consistent with flawed inferences from GWASs.
In conclusion, in a period of less than five years, the
GWAS experimental design in human populations has
led to new discoveries about genes and pathways involved
in common diseases and other complex traits, has
provided a wealth of new biological insights, has led to
discoveries with direct clinical utility, and has facilitated
basic research in human genetics and genomics. For the
future, technological advances enabling the sequencing
of entire genomes in large samples at affordable prices is
likely to generate additional genes, pathways, and biolog-
ical insights, as well as to identify causal mutations.Acknowledgments
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